SCHEMBL1948063

SCHEMBL1948063

O=S(=O)(Nc1cccc(CCc2ccccn2)c1)c1cc(Cl)sc1Cl

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.69
MAPT P10636 1/20 0.67
SMN1; SMN2 Q16637 3/20 0.60
HTT P42858 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
ALDH1A1 P00352 4/20 0.47
CDK1 P06493 1/20 0.46
CCNB1 P14635 1/20 0.46
CCNA2 P20248 1/20 0.46
CCND1 P24385 1/20 0.46
CDK2 P24941 1/20 0.46
CDK7 P50613 1/20 0.46
CCNH P51946 1/20 0.46
CCNA1 P78396 1/20 0.46
CDK6 Q00534 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1948202 0.84 MAPT (0.68) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL12563556 0.84 HSD11B1 (0.80) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL1947196 0.81 HSD11B1 (0.63) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL1945957 0.78 HSD11B1 (0.66) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL1947283 0.77 HSD11B1 (0.64) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL1945696 0.77 PFKFB3 (0.64) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL1945889 0.77 HSD11B1 (0.63) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL1947915 0.76 MAPT (0.72) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL1946616 0.75 MAPT (0.64) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL7579927 0.75 CDK1 (0.72) MAPTCDK1CCNB1CCNA2CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110130426-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2011-06-02 US disclosed
US-20110130426-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2011-06-02 US disclosed
US-20110130426-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2011-06-02 US disclosed
EP-1807405-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AstraZeneca AB (SE) 2007-07-18 EP disclosed
WO-2006046914-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES ASTRAZENECA AB (SE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130426-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 HSD11B1 16/4885MAPT 3552/4885SMN1; SMN2 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.